For the treatment of Central Nervous System Disorders
Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.
The Company’s lead clinical candidate, SRX246, is in a Phase II clinical trial for the treatment of Intermittent Explosive Disorder with an expected completion date in Q2 2016. Two additional Phase II clinical trials are being launched in 2016 for the treatment of irritability in Huntington’s Disease Patients (Q2) and for the treatment of PTSD (Q3).
MarketsStress, Mood, and Behavioral Disorders
Intermittent Explosive Disorder
severely impacts quality of life and poses substantial risk to patients. Current estimates indicate up to 6% lifetime prevalence in the US alone. There are currently no approved treatments.
Neuropsychiatric Symptoms in Huntington’s Disease.
Irritability and aggression are commonly observed in a high percentage of HD patients. These neuropsychiatric manifestations of HD are difficult to treat with existing pharmacologic and behavioral approaches and have major effects on the quality of life of HD subjects and their families.
Post-Traumatic Stress Disorder (PTSD)
is the most rapidly growing psychiatric diagnosis in the United States and a major issue for military medicine. Current treatments are repurposed drugs that are minimally effective.
Anger/Aggression/Impulse Control Disorders
are common co-morbidities impacting therapeutic response in multiple indications, including TBI, ADHD, PTSD, and personality disorders. There are currently no approved treatments.
Major Depression and Treatment Resistant Depression (TRD).
Some 50% of patients do not respond to current drug therapies; A novel, non-monoamine mechanism of action provides differentiation and an opportunity to address TRD.
Intermittent Explosive Disorder Phase II Clinical Trial
A Phase II clinical trial with SRX246 for the treatment of Intermittent Explosive Disorder will be completed in Q2 2016.
The National Institute of Neurological Diseases and Stroke awarded the Company a grant to conduct a Phase II trial with SRX246 in Huntington's Disease patients exhibiting irritability, a major neuropsychiatric symptom. The trial will launch in Q2 2016 in collaboration with the NINDS NeuroNext network.
The Department of Defense awarded the Company a grant to conduct a Phase II trial with SRX246 for the treatment of PTSD. Preparation for the trial is underway with enrollment beginning in Q3 2016.